ENGNW NASDAQ
enGene Holdings Inc. Warrants
1W: +35.2%
1M: -14.2%
3M: +14.9%
YTD: -91.2%
1Y: -64.6%
$0.23
+0.04 (+21.06%)
After Hours: $0.20 (-0.03, -11.59%)
Weekly Expected Move ±34.5%
$0
$0
$0
$0
$0
Credit Risk of going bust: higher than 96% of companies Debt: 23.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 91%), enGene Holdings Inc. Warrants would be worth roughly what it owes.
Total debt $33.3M against a stock market value of $105.9M.
Distance to default 0.41 (Merton model): prices to 2026-10-23, balance sheet 2026-07-31, debt counted $15.0M (short-term plus half of long-term), stock volatility 182.9%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $33.3M against a stock market value of $105.9M.
Distance to default 0.41 (Merton model): prices to 2026-10-23, balance sheet 2026-07-31, debt counted $15.0M (short-term plus half of long-term), stock volatility 182.9%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$11.8M
52W Range0.1113-4.2
Volume2,660
Avg Volume14,416
Beta-0.28
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORonald H. W. Cooper
Employees82
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-01
Websiteengene.com
4868 Rue Levy
Montreal, QC H4R 2P1
CA
Montreal, QC H4R 2P1
CA
514 332 4888
About enGene Holdings Inc. Warrants
EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CHEUNG ANTHONY TZEYE | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Giguere Lee | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Nichols Alexander Ju | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Daws D. Ryan | A-Award | 220,000 | $9.53 | 2026-01-30 |
| Cooper Ronald Harold | A-Award | 801,000 | $9.53 | 2026-01-30 |